International Psoriasis Council

Advancing Knowledge. Improving Care.

Remembering Dr. Wayne Gulliver

With great sadness, the International Psoriasis Council (IPC) shares that Dr. Wayne Gulliver, a long-serving IPC Councilor since 2012 and a luminous figure in dermatology and psoriasis research, has passed away.

Dr. Gulliver was a highly respected clinician, educator, and researcher whose impact on dermatology extended far beyond his home in Newfoundland, Canada. As a Professor Emeritus at Memorial University of Newfoundland and former Chair of the Discipline of Medicine, he devoted more than 35 years to advancing dermatologic research and education. He served as Principal Investigator in over 250 clinical trials, authored more than 200 peer-reviewed publications, and co-founded Newfound Genomics while serving as Chief Scientific Officer at NewLab Life Sciences.

His pioneering work in psoriasis care, hidradenitis suppurativa, wound healing, and dermatogenetics leaves an enduring legacy of innovation and mentorship. Dr. Gulliver’s guidance, compassion, and dedication to improving patients’ lives will continue to inspire the IPC community and the broader field of dermatology.

We extend our heartfelt condolences to his family, friends, colleagues, and all who were touched by his remarkable career and kindness.

IPC has made a donation in Dr. Gulliver’s memory to recognize his lasting impact on the psoriasis community. Those who wish to do the same may make contributions to First Light (Newfoundland and Labrador), the Prosthetics Department at the Miller Centre, or the Vera Perlin Society.

Read more about Dr. Gulliver’s remarkable career and lasting impact in the In Memoriam published in the Journal of the American Academy of Dermatology (JAAD), written by IPC President Bruce Strober.

Categories

Recent Posts

Approaching Challenging Patient Interactions with Empathy

Next Generation of Leaders: 2025 IPC Fellows Transition to Jr. Councilors

Highlights from the 2026 American Academy of Dermatology (AAD) Annual Meeting: Diagnostic Complexity, Therapeutic Advances, and Emerging Research

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026